File(s) under permanent embargo
Chasing the personalized medicine dream through biomarker validation in colorectal cancer.
journal contributionposted on 2017-01-01, 00:00 authored by Harshali Anant Patil, S G Saxena, Colin BarrowColin Barrow, Jagat Kanwar, Arnab KapatArnab Kapat, Rupinder Kanwar
Colorectal cancer (CRC) is a major health burden worldwide. The optimal approach to the diagnosis, management, and treatment of CRC involves multidisciplinary and integrated management practices. The field is rapidly changing because of recent advancements in delineating the molecular basis of tumorigenesis, introduction of targeted therapy, varied patient response to mainstay chemotherapeutics, biological drugs, and the effective combination regimes being used for treatment. Recent meta-analysis studies, which tend to establish few clinically useful predictor biomarkers, identify inconsistent results and limitations of the trials. Therefore, molecular pathological epidemiology discipline initiatives are promising. Here, we provide an overview of the potential of biomarker validation for personalized medicine by focusing largely on metastatic (m)CRC. We also highlight new candidate predictive and prognostic biomarkers.
JournalDrug discovery today
Pagination111 - 119
LocationAmsterdam, The Netherlands
Publication classificationC Journal article; C1 Refereed article in a scholarly journal
Copyright notice2016, Elsevier
Read the peer-reviewed publication
Science & TechnologyLife Sciences & BiomedicinePharmacology & PharmacyMETHYLENETETRAHYDROFOLATE REDUCTASE C677TMOLECULAR PATHOLOGICAL EPIDEMIOLOGYISLAND METHYLATOR PHENOTYPEMONOCLONAL-ANTIBODY THERAPYDIHYDROPYRIMIDINE DEHYDROGENASEMICROSATELLITE INSTABILITYTHYMIDINE PHOSPHORYLASEA1298C POLYMORPHISMSTHYMIDYLATE SYNTHASEPIK3CA MUTATION